Using Epigenetic Reprogramming to Treat Pediatric Brain Cancer.

abstract：:ErbB2, a metastasis-promoting oncoprotein, is overexpressed in approximately 25% of invasive/metastatic breast cancers, but in 50%-60% of noninvasive ductal carcinomas in situ (DCIS). It has been puzzling how a subset of ErbB2-overexpressing DCIS develops into invasive breast cancer (IBC). We found that co-overexpress...

journal_title：Cancer cell

authors： Lu J,Guo H,Treekitkarnmongkol W,Li P,Zhang J,Shi B,Ling C,Zhou X,Chen T,Chiao PJ,Feng X,Seewaldt VL,Muller WJ,Sahin A,Hung MC,Yu D

更新日期：2009-09-08 00:00:00

abstract：:The childhood brain tumor, medulloblastoma, includes four subtypes with very different prognoses. Here, we show that paracrine signals driven by mutant β-catenin in WNT-medulloblastoma, an essentially curable form of the disease, induce an aberrant fenestrated vasculature that permits the accumulation of high levels o...

journal_title：Cancer cell

authors： Phoenix TN,Patmore DM,Boop S,Boulos N,Jacus MO,Patel YT,Roussel MF,Finkelstein D,Goumnerova L,Perreault S,Wadhwa E,Cho YJ,Stewart CF,Gilbertson RJ

更新日期：2016-04-11 00:00:00

abstract：:Cell polarization is crucial during development and tissue homeostasis and is regulated by conserved proteins of the Scribble, Crumbs, and Par complexes. In mouse skin tumorigenesis, Par3 deficiency results in reduced papilloma formation and growth. Par3 mediates its tumor-promoting activity through regulation of grow...

journal_title：Cancer cell

authors： Iden S,van Riel WE,Schäfer R,Song JY,Hirose T,Ohno S,Collard JG

更新日期：2012-09-11 00:00:00

abstract：:The regulation and stem cell origin of normal and neoplastic gastric glands are uncertain. Here, we show that Mist1 expression marks quiescent stem cells in the gastric corpus isthmus. Mist1(+) stem cells serve as a cell-of-origin for intestinal-type cancer with the combination of Kras and Apc mutation and for diffuse...

journal_title：Cancer cell

authors： Hayakawa Y,Ariyama H,Stancikova J,Sakitani K,Asfaha S,Renz BW,Dubeykovskaya ZA,Shibata W,Wang H,Westphalen CB,Chen X,Takemoto Y,Kim W,Khurana SS,Tailor Y,Nagar K,Tomita H,Hara A,Sepulveda AR,Setlik W,Gershon MD,

更新日期：2015-12-14 00:00:00

abstract：:In this issue of Cancer Cell, demonstrate a novel mechanism for the oncogenic activity of MLL chimeric proteins. By providing coiled-coil or other dimerization domains, the cytoplasmic partners of MLL fusion proteins donate a platform for MLL homodimerization, allowing recruitment of accessory factors needed to activa...

journal_title：Cancer cell

authors： Hsu K,Look AT

更新日期：2003-08-01 00:00:00

abstract：:Constitutive activation of NF-κB signaling can promote oncogenesis, providing a rationale for anticancer strategies that inhibit NF-κB signaling. Two recent publications in Genes & Development provide evidence that, in contexts where prosurvival signals derive from other oncogenes, NF-κB activity instead enhances sens...

journal_title：Cancer cell

authors： Klein U,Ghosh S

更新日期：2011-11-15 00:00:00

abstract：:Inhibition of ERK-MAPK signaling by expression of dominant-negative MEK1 in the tumor vasculature suppresses angiogenesis and tumor growth. In an organotypic tissue culture angiogenesis assay, ERK-MAPK inhibition during the migratory phase results in loss of bipolarity, detachment, and cell death of isolated endotheli...

journal_title：Cancer cell

authors： Mavria G,Vercoulen Y,Yeo M,Paterson H,Karasarides M,Marais R,Bird D,Marshall CJ

更新日期：2006-01-01 00:00:00

abstract：:Targeted protein degradation is an emerging technology for drug development. An article published in Nature reported a novel mechanism of targeted protein degradation triggered by small-molecule-induced polymerization of the oncogenic transcription factor BCL6. ...

journal_title：Cancer cell

authors： Naito M,Murata S

更新日期：2021-01-11 00:00:00

abstract：:Agonistic antibodies specific for members of the tumor necrosis factor receptor protein family hold great promise for immunotherapy of cancer. In this issue of Cancer Cell, White and colleagues provide evidence that the human IgG2 subclass may represent a superior backbone for the use of these antibodies in human ther...

journal_title：Cancer cell

authors： Lux A,Nimmerjahn F

更新日期：2015-01-12 00:00:00

abstract：:Aneuploidy is a hallmark of cancer, although its effects on tumorigenesis are unclear. Here, we investigated the relationship between aneuploidy and cancer development using cells engineered to harbor single extra chromosomes. We found that nearly all trisomic cell lines grew poorly in vitro and as xenografts, relativ...

journal_title：Cancer cell

authors： Sheltzer JM,Ko JH,Replogle JM,Habibe Burgos NC,Chung ES,Meehl CM,Sayles NM,Passerini V,Storchova Z,Amon A

更新日期：2017-02-13 00:00:00

abstract：:The tumor suppressor cylindromatosis (CYLD) inhibits the NFκB and mitogen-activated protein kinase (MAPK) activation pathways by deubiquitinating upstream regulatory factors. Here we show that liver-specific disruption of CYLD triggers hepatocyte cell death in the periportal area via spontaneous and chronic activation...

journal_title：Cancer cell

authors： Nikolaou K,Tsagaratou A,Eftychi C,Kollias G,Mosialos G,Talianidis I

更新日期：2012-06-12 00:00:00

abstract：:Antiangiogenic tumor therapy has failed in the adjuvant setting. Here we show that inhibition of the Tie2 ligand angiopoietin-2 (Ang2) effectively blocks metastatic growth in preclinical mouse models of postsurgical adjuvant therapy. Ang2 antibody treatment combines well with low-dose metronomic chemotherapy (LDMC) in...

journal_title：Cancer cell

authors： Srivastava K,Hu J,Korn C,Savant S,Teichert M,Kapel SS,Jugold M,Besemfelder E,Thomas M,Pasparakis M,Augustin HG

更新日期：2014-12-08 00:00:00

abstract：:We evaluated ancestry effects on mutation rates, DNA methylation, and mRNA and miRNA expression among 10,678 patients across 33 cancer types from The Cancer Genome Atlas. We demonstrated that cancer subtypes and ancestry-related technical artifacts are important confounders that have been insufficiently accounted for....

journal_title：Cancer cell

authors： Carrot-Zhang J,Chambwe N,Damrauer JS,Knijnenburg TA,Robertson AG,Yau C,Zhou W,Berger AC,Huang KL,Newberg JY,Mashl RJ,Romanel A,Sayaman RW,Demichelis F,Felau I,Frampton GM,Han S,Hoadley KA,Kemal A,Laird PW,Lazar AJ

更新日期：2020-05-11 00:00:00

abstract：:T cell engineering is a powerful means to rapidly generate anti-tumor T cells. The costimulatory properties of second-generation chimeric antigen receptors (CARs) determine the overall potency of adoptively transferred T cells. Using an in vivo "stress test" to challenge CD19-targeted T cells, we studied the functiona...

journal_title：Cancer cell

authors： Zhao Z,Condomines M,van der Stegen SJC,Perna F,Kloss CC,Gunset G,Plotkin J,Sadelain M

更新日期：2015-10-12 00:00:00

abstract：:Multiple angiogenesis inhibitors have been therapeutically validated in preclinical cancer models, and several in clinical trials. Here we report that angiogenesis inhibitors targeting the VEGF pathway demonstrate antitumor effects in mouse models of pancreatic neuroendocrine carcinoma and glioblastoma but concomitant...

journal_title：Cancer cell

authors： Pàez-Ribes M,Allen E,Hudock J,Takeda T,Okuyama H,Viñals F,Inoue M,Bergers G,Hanahan D,Casanovas O

更新日期：2009-03-03 00:00:00

abstract：:It is widely accepted that metastasis is a late event in cancer progression. Here, however, we show that tumor cells can disseminate systemically from earliest epithelial alterations in HER-2 and PyMT transgenic mice and from ductal carcinoma in situ in women. Wild-type mice transplanted with single premalignant HER-2...

journal_title：Cancer cell

authors： Hüsemann Y,Geigl JB,Schubert F,Musiani P,Meyer M,Burghart E,Forni G,Eils R,Fehm T,Riethmüller G,Klein CA

更新日期：2008-01-01 00:00:00

abstract：:Advanced stage papillary serous tumors of the ovary are responsible for the majority of ovarian cancer deaths, yet the molecular determinants modulating patient survival are poorly characterized. Here, we identify and validate a prognostic gene expression signature correlating with survival in a series of microdissect...

journal_title：Cancer cell

authors： Mok SC,Bonome T,Vathipadiekal V,Bell A,Johnson ME,Wong KK,Park DC,Hao K,Yip DK,Donninger H,Ozbun L,Samimi G,Brady J,Randonovich M,Pise-Masison CA,Barrett JC,Wong WH,Welch WR,Berkowitz RS,Birrer MJ

更新日期：2009-12-08 00:00:00

abstract：:Loss of p53 is considered to allow progression of colorectal tumors from the adenoma to the carcinoma stage. Using mice with an intestinal epithelial cell (IEC)-specific p53 deletion, we demonstrate that loss of p53 alone is insufficient to initiate intestinal tumorigenesis but markedly enhances carcinogen-induced tum...

journal_title：Cancer cell

authors： Schwitalla S,Ziegler PK,Horst D,Becker V,Kerle I,Begus-Nahrmann Y,Lechel A,Rudolph KL,Langer R,Slotta-Huspenina J,Bader FG,Prazeres da Costa O,Neurath MF,Meining A,Kirchner T,Greten FR

更新日期：2013-01-14 00:00:00

abstract：:Neuroblastoma is an embryonal tumor of the sympathetic nervous system and the most common extracranial tumor of childhood. By sequencing transcriptomes of low- and high-risk neuroblastomas, we detected differentially expressed annotated and nonannotated long noncoding RNAs (lncRNAs). We identified a lncRNA neuroblasto...

journal_title：Cancer cell

authors： Pandey GK,Mitra S,Subhash S,Hertwig F,Kanduri M,Mishra K,Fransson S,Ganeshram A,Mondal T,Bandaru S,Ostensson M,Akyürek LM,Abrahamsson J,Pfeifer S,Larsson E,Shi L,Peng Z,Fischer M,Martinsson T,Hedborg F,Kogner P,

更新日期：2014-11-10 00:00:00

abstract：:Obesity increases hepatocellular carcinoma (HCC) risks via unknown mediators. We report that hepatic unconventional prefoldin RPB5 interactor (URI) couples nutrient surpluses to inflammation and non-alcoholic steatohepatitis (NASH), a common cause of HCC. URI-induced DNA damage in hepatocytes triggers inflammation via...

journal_title：Cancer cell

authors： Gomes AL,Teijeiro A,Burén S,Tummala KS,Yilmaz M,Waisman A,Theurillat JP,Perna C,Djouder N

更新日期：2016-07-11 00:00:00

abstract：:PIK3R1 (p85α regulatory subunit of PI3K) is frequently mutated across cancer lineages. Herein, we demonstrate that the most common recurrent PIK3R1 mutation PIK3R1(R348∗) and a nearby mutation PIK3R1(L370fs), in contrast to wild-type and mutations in other regions of PIK3R1, confers an unexpected sensitivity to MEK an...

journal_title：Cancer cell

authors： Cheung LW,Yu S,Zhang D,Li J,Ng PK,Panupinthu N,Mitra S,Ju Z,Yu Q,Liang H,Hawke DH,Lu Y,Broaddus RR,Mills GB

更新日期：2014-10-13 00:00:00

abstract：:In this issue of Cancer Cell, Sturm et al. report that global DNA methylation patterns in glioblastoma multiforme divide adult and pediatric tumors into subgroups that have characteristic DNA mutations, mRNA profiles, and most importantly, different clinical behaviors. These findings suggest novel opportunities for th...

journal_title：Cancer cell

authors： Raabe EH,Eberhart CG

更新日期：2012-10-16 00:00:00

abstract：:The involvement of the homologous to E6-AP carboxyl terminus (HECT)-type E3s in crucial signaling pathways implicated in tumorigenesis is presently an area of intense research and extensive scientific interest. This review highlights recent discoveries on the ubiquitin-mediated degradation of crucial tumor suppressor ...

journal_title：Cancer cell

authors： Bernassola F,Karin M,Ciechanover A,Melino G

更新日期：2008-07-08 00:00:00

abstract：:Immunotherapy has changed the landscape of cancer treatment. Checkpoint blockade therapies unleash breaks in the immune system and induce long-lasting responses. However, a significant number of patients do not respond (innate resistance), and a subset progress after responding (acquired resistance). A better understa...

journal_title：Cancer cell

authors： Abril-Rodriguez G,Ribas A

更新日期：2017-06-12 00:00:00

abstract：:Ras proteins play a major role in human cancers but have not yielded to therapeutic attack. Ras-driven cancers are among the most difficult to treat and often excluded from therapies. The Ras proteins have been termed "undruggable," based on failures from an era in which understanding of signaling transduction, feedba...

journal_title：Cancer cell

authors： Stephen AG,Esposito D,Bagni RK,McCormick F

更新日期：2014-03-17 00:00:00

abstract：:In this issue of Cancer Cell, Volk et al. report that overexpression of CHAF1B displaces myeloid transcription factors from chromatin, and deletion of CHAF1B promotes differentiation of leukemia cells and suppresses leukemogenesis in a murine model, revealing a causal role of and an unexpected mechanism for CHAF1B ove...

journal_title：Cancer cell

authors： Li Q,Zhang X,Zhang Z

更新日期：2018-11-12 00:00:00

abstract：:Adenosine deaminase associated with RNA1 (ADAR1) deregulation contributes to therapeutic resistance in many malignancies. Here we show that ADAR1-induced hyper-editing in normal human hematopoietic progenitors impairs miR-26a maturation, which represses CDKN1A expression indirectly via EZH2, thereby accelerating cell-...

journal_title：Cancer cell

authors： Jiang Q,Isquith J,Zipeto MA,Diep RH,Pham J,Delos Santos N,Reynoso E,Chau J,Leu H,Lazzari E,Melese E,Ma W,Fang R,Minden M,Morris S,Ren B,Pineda G,Holm F,Jamieson C

更新日期：2019-01-14 00:00:00

abstract：:Transcriptional profiling of two isogenic models of transformation identifies a gene signature linking cancer with inflammatory and metabolic diseases. In accord with this common transcriptional program, many drugs used for treatment of diabetes and cardiovascular diseases inhibit transformation and tumor growth. Unex...

journal_title：Cancer cell

authors： Hirsch HA,Iliopoulos D,Joshi A,Zhang Y,Jaeger SA,Bulyk M,Tsichlis PN,Shirley Liu X,Struhl K

更新日期：2010-04-13 00:00:00

abstract：:Therapies that target estrogen signaling have transformed the treatment of breast cancer. However, the effectiveness of these agents is limited by the development of resistance. Here, an RNAi screen was used to identify modifiers of tamoxifen sensitivity. We demonstrate that CDK10 is an important determinant of resist...

journal_title：Cancer cell

authors： Iorns E,Turner NC,Elliott R,Syed N,Garrone O,Gasco M,Tutt AN,Crook T,Lord CJ,Ashworth A

更新日期：2008-02-01 00:00:00

abstract：:Immune checkpoint-blockade treatments targeting PD-1/PD-L1 have revolutionized cancer therapy. Hence, understanding the regulation of PD-L1 expression has major clinical relevance. In this issue of Cancer Cell, Lim et al. report that inflammation-induced and NF-κB-driven expression of deubiquitinating enzyme CSN5 lead...

journal_title：Cancer cell

authors： Grinberg-Bleyer Y,Ghosh S

更新日期：2016-12-12 00:00:00